Difference between revisions of "Pamidronate (Aredia)"
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/aredia.pdf Pamidronate (Aredia) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/pamidronate.pdf Pamidronate (Aredia) package insert (locally hosted backup)]</ref><ref>[http://www.pamidronate.com Pamidronate manufacturer's website]</ref> | Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.<ref name="insert">[http://www.pharma.us.novartis.com/product/pi/pdf/aredia.pdf Pamidronate (Aredia) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/pamidronate.pdf Pamidronate (Aredia) package insert (locally hosted backup)]</ref><ref>[http://www.pamidronate.com Pamidronate manufacturer's website]</ref> | ||
| Line 10: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/pamidronate-patient-drug-information Pamidronate (Aredia) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pamidronate-patient-drug-information Pamidronate (Aredia) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/pamidronate-patient-drug-information Pamidronate (Aredia) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/pamidronate-patient-drug-information Pamidronate (Aredia) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==Also known as== | ||
| + | pamidronate disodium omega, Pamisol, PMS-pamidronate, or Rhoxal-pamidronate. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Bisphosphonates]] | ||
Revision as of 04:04, 10 January 2014
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption. Exact mechanism not understood, but is believed to also involve blocking dissolution of bone calcium phosphate (hydroxyapatite) crystals.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
Also known as
pamidronate disodium omega, Pamisol, PMS-pamidronate, or Rhoxal-pamidronate.